Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including one "Best of ASH" presentation on Waldenstrom's macroglobulinemia (WM). In total, 33 additional pre-clinical and non-clinical presentations provided new discoveries using ibrutinib; seven of these were oral presentations. The presentations further elucidated the mechanism of action of ibrutinib and its effect in the tumor microenvironment and provided data on quality of life changes. Results covered various B-cell malignancies: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), WM, and non-Hodgkin lymphoma (NHL).

"The breadth of data presented at ASH this year demonstrates the scientific community's interest in ibrutinib and builds on the clinical responses seen with ibrutinib as a backbone of combination therapy and as a single agent in multiple B-cell malignancies," said Jesse McGreivy, M.D., Chief Medical Officer, Pharmacyclics. "This year's data explain ibrutinib's effect on the quality of life for patients and build on impressive efficacy and safety results, independent of cytogenetic risk factors. We also now have long-term follow-up in CLL, which suggests continuation of the efficacy and a decrease in overall and severe adverse events."

Clinical Trial Presentation Highlights

Chronic Lymphocytic Leukemia

-POSTER PRESENTATION- Abstract #4163:
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibruti
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 STAAR Surgical Company (NASDAQ: ... marketer of implantable lenses and delivery systems for the ... results and conference call with investors to July 31, ... The Company rescheduled the release date and conference call ... for Hideo Watanabe , President of STAAR Japan, ...
(Date:7/28/2014)... Calif. , July 28, 2014 KaloBios ... an update on the status of the KB001-A development ... Sanofi Pasteur.  KB001-A Collaboration Update ... agreement with Sanofi Pasteur to regain all rights to ... licensing agreement entered into in 2010 has been terminated. ...
(Date:7/28/2014)... RESTON, Va. , July 28, 2014 /PRNewswire/ ... management services, announced the Company has been awarded ... Medical Support Command (NEMSCOM) and its Deployable Medical ... to enable medical personnel to provide world-class healthcare ... any operating environment across the globe. The five ...
Breaking Medicine Technology:STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... 7 Hawaii Biotech, Inc. announced today,that it has ... Administration,(FDA) that it may proceed to initiate a 24 ... subunit West Nile vaccine. The trial,will be conducted at ... to start in April 2008, pending successful completion of ...
... 7 Celldex Therapeutics,announced today that the U.S. ... designation to Celldex,s CDX-110 for the treatment of,EGFRvIII ... common,and aggressive form of primary brain cancer and ... is an immunotherapy that targets,the tumor-specific growth promoter ...
Cached Medicine Technology:Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials 2Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 2Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 3Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 4Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 5
(Date:7/29/2014)... The National Foundation for Infectious ... ASAE Power of A Silver Award winner for ... encourage everyone age six months and older to be ... for its power to enrich lives through its steady ... and professionals about the importance of vaccination. ...
(Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign for ... embarrassing odors in the office. PoofPad is a discrete bag ... desk drawer. This compact packaging is designed for ease of ... the pad and poof away! , “We’ve all been there. ... appears out of nowhere. It’s embarrassing and unpleasant for everyone ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 "Acceptance, Recognition, ... man who faced his own demons and wants other men ... intended life partner left. A month later, he had no ... longer pay. When Raymond approached the government for assistance, the ... a two-year counselling program. But this approach didn’t get to ...
(Date:7/29/2014)... Current Back2Basics long-term drug rehab ... foot surgery during his first six months of sobriety. ... twice on one foot, once on the other– which was ... foot a year ago and was prescribed drugs that I ... a friend from home who’d recently completed the program. The ...
(Date:7/29/2014)... Consilium Staffing, Your Partner in Locum Tenens, is reporting ... 2014, with strong indications the Irving, Texas-based firm will reach ... , “This is a great time to be at Consilium,” ... , “We are proud of what we have accomplished in ... more excited about how things are shaping up for the ...
Breaking Medicine News(10 mins):Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2Health News:Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2
... NEW YORK, May 28 The UltraPulse CO2 fractional ... as an exciting and revolutionary new treatment for ... in a fire as infants told their personal story ... After only two treatments with the groundbreaking ActiveFX and ...
... Results Published in May Issue of Ostomy Wound ... nurses and people living with an ostomy reported ... moldable skin barrier pioneered by ConvaTec Ostomy Care, ... this month in the journal Ostomy Wound ...
... Amex: CXM ) and its subsidiary Tissue ... 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of ... Symposium at the American Society of Gene Therapy (ASGT) ... 2009. Dr. Barbara K. Sosnowski, Cardium,s Vice President ...
... to Vote WHITE Proxy Card to Re-Elect Highly-Qualified ... Opposition SlateTUCSON, Ariz., May 28 The Providence ... announced that it has issued the following letter ... to vote at the upcoming 2009 Annual Meeting ...
... Fla., May 28 As a service to ... PR Newswire will be posting event related news ... into a dedicated event news archive for this ... ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20000306/PRNLOGO ...
... ALISO VIEJO, Calif., May 28 Valeant Pharmaceuticals International ... board of directors has authorized the repurchase of an ... common stock under the securities repurchase program approved in ... repurchase authorization to $500 million from $200 million over ...
Cached Medicine News:Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 2Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 4Health News:Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier 2Health News:Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier 3Health News:Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 2Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 3Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 5Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 6Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 7Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 8Health News:Providence Service Corporation Issues Letter to Stockholders 2Health News:Providence Service Corporation Issues Letter to Stockholders 3Health News:Providence Service Corporation Issues Letter to Stockholders 4Health News:Providence Service Corporation Issues Letter to Stockholders 5Health News:Providence Service Corporation Issues Letter to Stockholders 6Health News:Providence Service Corporation Issues Letter to Stockholders 7Health News:Providence Service Corporation Issues Letter to Stockholders 8Health News:Providence Service Corporation Issues Letter to Stockholders 9Health News:2009 ASCO Annual Meeting and Conference News Distributed by PR Newswire Available at www.EventNewsCenter.com 2Health News:2009 ASCO Annual Meeting and Conference News Distributed by PR Newswire Available at www.EventNewsCenter.com 3Health News:Valeant Announces Increase to Securities Repurchase Program 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: